QUAIL
发表于 2025-3-30 09:47:38
http://reply.papertrans.cn/23/2281/228051/228051_51.png
Cytokines
发表于 2025-3-30 15:43:12
New Agents for the Treatment of T-Cell Acute Lymphoblastic Leukemiagher frequency of induction failure and early relapse compared to B-cell acute lymphoblastic leukemia (B-ALL). Although treated with similar regimens, T-ALL is biologically distinct from B-ALL and shows a different kinetic pattern of disease response. While minimal residual disease (MRD) response re
Calculus
发表于 2025-3-30 17:00:08
The Development and Management of Treatment with Chimeric Antigen Receptor T Cell (CAR T)t, tisagenlecleucel, for the treatment of relapsed and refractory B-ALL. Despite this success, several limitations of current CAR T cell products preclude the reliable use of this therapy as a durable curative treatment. Challenges in CAR T cell product manufacture, leukemia resistance to targeted t
疯狂
发表于 2025-3-30 21:26:21
http://reply.papertrans.cn/23/2281/228051/228051_54.png
Truculent
发表于 2025-3-31 01:49:05
http://reply.papertrans.cn/23/2281/228051/228051_55.png
Interim
发表于 2025-3-31 05:39:05
http://reply.papertrans.cn/23/2281/228051/228051_56.png
Rejuvenate
发表于 2025-3-31 12:26:44
,La régression linéaire multiple,basis of B-progenitor ALL. These studies have identified multiple new subtypes of B-ALL and have shown that many of these new subtypes are driven by diverse genetic alterations in addition to those previously characterized by aneuploidy or a single fusion oncoprotein. These include subtypes driven b
军械库
发表于 2025-3-31 16:46:17
,Régression sur variables qualitatives,l growth, proliferation, and survival disruption in early T-cell progenitors and disrupt transcriptional programs that control early thymocyte development. Highly prevalent genetic lesions induce constitutive activation of NOTCH1 signaling, deregulated cell cycle progression, and aberrant JAK-STAT,